Peptides
Tirzepatide (Mounjaro)
Also called Mounjaro · Tirz · Zepbound
Tirzepatide helps reduce appetite and supports weight loss or diabetes treatment. In the US, Zepbound is the weight-management brand and Mounjaro treats type 2 diabetes. Both are weekly injections, with different dosing instructions.
Dosage & duration
Adults · current US product labels · injections under the skin.
Zepbound · weight management
Product label- Dose
- Start: 2.5 mg for 4 weeks, then 5 mg. After gradual increases: 5, 10 or 15 mg maintenance; maximum 15 mg.
- How often
- Once weekly
- How long
- Long-term treatment; no fixed label course
Further increases use 2.5 mg steps after at least 4 weeks at the current dose, considering response and tolerability. The 2.5 mg dose is introductory, not maintenance.
Sources: 1
Mounjaro · type 2 diabetes
Product label- Dose
- Start: 2.5 mg. If more blood-sugar control is needed: increases of 2.5 mg after at least 4 weeks at the current dose; adult maximum 15 mg.
- How often
- Once weekly
- How long
- Ongoing treatment; no fixed label course
Current US diabetes instructions make increases conditional. Reaching week 5 does not automatically mean moving to 5 mg; Zepbound’s starter-only rule is different.
Label context, not a personal prescription or a conversion between products. The weight-management entry does not replace Zepbound’s separate sleep-apnea instructions.
One dose · modeled timing
Why weekly tirzepatide doses overlap
100% = the model’s peak, not the dose left or a blood-test result.
About this curve
Some drug remains when the next injection is due. Repeated weekly doses gradually build toward a recurring pattern.
- A dose fades over days
- The drug is absorbed after injection and removed gradually.
- Earlier doses still contribute
- A consistent weekly schedule builds toward a repeating pattern over several weeks.
Fixed study-model example: 90 kg adult woman, BMI 32.5. The curve is normalized to this model’s peak. It explains timing, not the percentage of a dose remaining, appetite strength or expected weight loss.
Model assumptions and sourcesWhat changes do people hope to notice?
People seek less hunger and weight loss, or better blood-sugar control when they have type 2 diabetes. The useful measure of progress depends on the treatment goal; feeling no hunger at all is not the goal.
In SURMOUNT-1, adults with obesity or overweight and a weight-related complication, without diabetes, received tirzepatide alongside lifestyle support. Average weight loss at 72 weeks was 15.0%, 19.5% and 20.9% in the 5, 10 and 15 mg groups, versus 3.1% with placebo. These results followed gradual increases and months of treatment, not a starting-dose test.
For lifters: losing weight while keeping training on track
Physique discussions focus on easier cutting, muscle retention and whether reduced appetite makes eating around training difficult. Some describe much less food preoccupation; others still report cravings despite weight loss. Hunger alone is a poor measure of body-composition progress.
In the SURMOUNT-1 body-composition substudy, adults with obesity or overweight lost both fat and lean mass. Lean mass includes more than skeletal muscle, so this is not a personal muscle-loss forecast. The study did not establish a muscle-preserving regimen for lean bodybuilders.
Mounjaro or Zepbound: what is different?
Both contain tirzepatide. In the US, Mounjaro treats type 2 diabetes; Zepbound is used for weight management and has a separate sleep-apnea indication in adults with obesity. Other countries may license them differently.
Their dose instructions differ: Zepbound has a specified introductory step, while Mounjaro’s current US label makes increases conditional on needing more blood-sugar control. The visible guide separates them. A shared ingredient does not make every device or instruction interchangeable.
Which side effects deserve attention?
Nausea, diarrhea, constipation and vomiting are common, especially during increases. Persistent vomiting, inability to keep fluids down or severe, persistent abdominal pain need medical attention. Insulin or sulfonylurea users also need a plan for low-blood-sugar risk.
The labels advise non-oral contraception or additional barrier protection for four weeks after starting and after each increase. They also cover gallbladder and pancreatic problems, severe stomach-emptying problems, and the medullary thyroid cancer/MEN 2 contraindication.
What happens after stopping?
In SURMOUNT-4, people switched to placebo after initial tirzepatide treatment regained weight over the following year, while those continuing lost more. Maintenance needs its own follow-up plan. A short cutting cycle or a blood-level chart cannot answer that question.
Model details: Tirzepatide (Mounjaro)
How to read this chart
This is a study-based example of how tirzepatide levels change over time. Try different doses or timing to compare the curves.
The calculation uses the same assumptions for everyone. It can't predict your own blood levels or tell you what dose to take.
Study setup and sources
Tirzepatide: drug concentration in plasma (nmol/L).
Fixed reference profile: Constructed adult female reference with type 2 diabetes: 90 kg and BMI 32.5 kg/m²; not a published average participant. Subcutaneous tirzepatide in the published pooled-study model, using its estimated relative-bioavailability scenario; Subcutaneous. Fixed reference weight: 90 kg.
Changing dose or schedule explores a scenario; it does not personalize the reference profile or establish a studied regimen.
Input dose basis: Milligrams of tirzepatide, not solution volume, syringe units or a product conversion.
Source exposure scope: The source pooled single and repeated subcutaneous dosing across phase I–III studies. Entered schedules are simulations, not treatment instructions.
Published two-compartment model: constructed 90 kg female reference
tirzepatide-schneck-2024-fixed-reference · version 1
- Body weight, sex and BMI stay fixed. Fat-free mass 49.9282 kg and fat mass 40.0718 kg are calculated from the published female equation.
- Clearance and intercompartmental clearance scale with (90/70)^0.8; both volumes scale with (fat-free mass + 0.482 × fat mass)/70.
- Effective availability is 0.8 × (1 − 0.181) = 0.6552, the supplementary model setting for pooled studies other than the phase-I absolute-bioavailability reference study (STUDYN=4). It is applied once.
- Individual random effects are zero. No weight-loss trajectory or pre-existing tirzepatide is assumed before the entered dose history.
- Model structure
- Two compartments with absorption
- Clearance (CL)
- 0.04022643 L/hour
- Central volume (Vc)
- 2.443282 L
- Absorption rate (ka)
- 0.0373 /hour
- Intercompartmental clearance (Q)
- 0.1540587 L/hour
- Peripheral volume (Vp)
- 3.936948 L
- Bioavailability (F)
- 65.52%
- Input mass conversion
- 1 mg modelled mass per mg entered
- This is a fixed scenario from the published population model, not an individual prediction or a published mean concentration profile.
- The source allowed body weight to change over time; this implementation freezes body size and does not simulate parameter variability or uncertainty bands.
- The between-study availability term is model context, not evidence that every marketed, compounded or investigational formulation shares this availability.
- Concentration does not predict treatment response, tolerability or a safe dose. A clearance threshold is not a safety or testing guarantee.
- Schneck and Urva 2024 — population pharmacokinetics of tirzepatide
Table 3 and equations 5–8: two-compartment coefficients, female fat-free mass, total-weight clearance scaling, adjusted-fat-mass volume scaling and F = 0.8 × (1 − 0.181). Parameters here are derived for the explicitly constructed reference.
- Lilly Mounjaro prescribing information
Section 11 supplies molecular weight for mass-to-molar conversion. Label mean apparent clearance and volume are population summaries, not interchangeable structural coefficients.
- Schneck and Urva — supplementary executable model
Supplementary Attachment 2 NONMEM: BIOPHS=1+THETA(10), except STUDYN=4. Table 3 Vp=3.98 L/70 kg is used here, versus 3.97 in the supplementary code; this source-version discrepancy is retained explicitly.
Common questions
Is 2.5 mg always just a starter dose?
For Zepbound, yes: the US label identifies 2.5 mg as initiation only and specifies 5 mg after four weeks. Mounjaro’s current US label differs: it starts at 2.5 mg and makes further increases conditional on additional blood-sugar control after at least four weeks.
Does being hungry before the next injection mean it has worn off?
Not necessarily. Tirzepatide remains between weekly injections, and hunger is not a direct blood-level measurement. Review a recurring problem with the prescriber instead of using one hungry day to select an earlier injection or larger dose.
Does tirzepatide produce more weight loss than semaglutide?
In SURMOUNT-5, adults without diabetes lost more weight on average with tirzepatide 10/15 mg than with semaglutide 1.7/2.4 mg over 72 weeks. That supports the comparison at those trial doses; it does not predict everyone’s result or compare newer 7.2 mg semaglutide.
Do Mounjaro and Zepbound need reconstitution?
The approved US products are supplied as liquid solutions with product-specific pen or vial instructions. A generic powder-mixing recipe does not apply, and the total amount in a multidose device is not the amount of one injection.
Sources Labels, studies and notes behind this guide
Catalog evidence: Human clinical trials. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- What people seek
- Tirzepatide acts on the GIP and GLP-1 hormone pathways. The reason for treatment determines which outcomes and product instructions matter.
- US brand distinction
- The same ingredient does not make every indication, dose instruction or device interchangeable.
- Common trade-offs
- Digestive effects are often more noticeable during dose escalation. A larger dose is not automatically a better fit.
- 1. Zepbound US prescribing information — August 2026
Adult weight-management context: 2.5 mg weekly for four weeks then 5 mg; further 2.5 mg increases after at least four weeks, selected for response/tolerability; recommended maintenance 5/10/15 mg and maximum 15 mg. OSA has separate 10/15 mg maintenance. Sections 1, 2, 5–8 and 12 cover purpose, risks, contraception and 5–6-day half-life.
- 2. Mounjaro US prescribing information — August 2026
Adult type 2 diabetes context: start 2.5 mg weekly; increase by 2.5 mg only if additional glycemic control is needed after at least four weeks at the current dose. Adult maximum 15 mg. Current label has no mandatory week-five 5 mg step or fixed maintenance list. Approved product is a prepared injection solution; devices/concentrations vary.
- 3. DailyMed — current Mounjaro dosing
Current August 2026 section 2.1 independently rechecked: conditional 2.5 mg increases after at least four weeks, adult maximum 15 mg, separate pediatric maximum 10 mg. Not the Zepbound starter-only schedule.
- 4. Schneck and Urva 2024 — tirzepatide population model
The existing reference uses a constructed 90 kg adult woman with BMI 32.5 and the declared between-study adjustment. PK/defaults are unchanged; the normalized timing visual is not an appetite or personal weight-loss prediction.
- 5. Schneck and Urva 2024 — population pharmacokinetics of tirzepatide
Table 3 and equations 5–8: two-compartment coefficients, female fat-free mass, total-weight clearance scaling, adjusted-fat-mass volume scaling and F = 0.8 × (1 − 0.181). Parameters here are derived for the explicitly constructed reference.
- 6. Lilly Mounjaro prescribing information
Section 11 supplies molecular weight for mass-to-molar conversion. Label mean apparent clearance and volume are population summaries, not interchangeable structural coefficients.
- 7. Schneck and Urva — supplementary executable model
Supplementary Attachment 2 NONMEM: BIOPHS=1+THETA(10), except STUDYN=4. Table 3 Vp=3.98 L/70 kg is used here, versus 3.97 in the supplementary code; this source-version discrepancy is retained explicitly.
- 8. Jastreboff et al. 2022 — SURMOUNT-1
2,539 adults with obesity or overweight plus a weight-related complication, excluding diabetes. Weekly 5/10/15 mg or placebo for 72 weeks, including escalation and lifestyle intervention. Mean weight reductions 15.0/19.5/20.9% versus 3.1% placebo under the treatment-regimen analysis; not starting-month or individual predictions.
- 9. Aronne et al. 2025 — SURMOUNT-5
751 adults without type 2 diabetes, direct open-label randomized 72-week comparison. Highest tolerated tirzepatide 10/15 mg versus semaglutide 1.7/2.4 mg: mean weight loss 20.2% versus 13.7%. Newer 7.2 mg semaglutide and tablets were not compared.
- 10. Aronne et al. — SURMOUNT-4 withdrawal trial
After a 36-week tirzepatide lead-in, participants were randomized to continued treatment or placebo for 52 weeks. Withdrawal led to regain while continuation maintained/extended reduction; a maintenance question, not a fixed recommended cycle.
- 11. Wegovy US prescribing information — June 2026
Current selected-adult 7.2 mg weight-management option is outside the older SURMOUNT-5 comparator doses; used only for that comparison boundary.
- 12. Look et al. — SURMOUNT-1 body-composition substudy (2025)
Primary DXA substudy: 160 analyzed participants with obesity or overweight, followed for 72 weeks; both fat and lean mass decreased. DXA lean mass is not a direct measure of skeletal muscle or trained-lifter outcomes.
Keep reading
Related compounds and examples
Related compounds
Semaglutide Injection (Ozempic/Wegovy)
Semaglutide can reduce hunger and food intake, helping people lose weight. Wegovy injections are prescribed for weight management; Ozempic injections treat type 2 diabetes. Both are taken weekly, with gradual dose increases to help manage digestive side effects.
Semaglutide Oral (Rybelsus)
Oral semaglutide offers a daily tablet option for adults with type 2 diabetes who want to avoid injections. The morning routine matters: food, drink and other tablets affect absorption, and different semaglutide products cannot be compared milligram for milligram.
Retatrutide
Retatrutide is an experimental weekly injection attracting interest for substantial weight loss and appetite-related effects. It adds a third hormone pathway to the approach used by tirzepatide. Large trials have reported results, but retatrutide remains unapproved and has no approved prescribing dose.